FDA Grants Orphan Drug Status to Cudetaxestat

FDA Grants Orphan Drug Status to Cudetaxestat

309903

FDA Grants Orphan Drug Status to Cudetaxestat

Cudetaxestat, a potential anti-scarring medication, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of scleroderma. “There are limited options and high medical need for patients suffering from systemic sclerosis [SSc, or scleroderma],” Daven Mody, vice president of regulatory affairs with Blade Therapeutics, the company developing cudetaxestat, said in a press release. “We look forward to continuing our clinical development efforts for cudetaxestat in lung fibrosis [scarring]…

You must be logged in to read/download the full post.